By Josh Beckerman

LAVA Therapeutics NV shares were up 7% to $7.70 Wednesday after a potential treatment of chronic lymphocytic leukemia received an orphan drug designation from the U.S. Food and Drug Administration.

The FDA lists the generic name of the potential treatment as immunoglobulin VHH fragment-linker-VHH fragment, anti-CD1d and anti-[Vdelta2 T-cell receptor], humanized monoclonal antibody.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

October 13, 2021 14:36 ET (18:36 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more LAVA Therapeutics NV Charts.
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more LAVA Therapeutics NV Charts.